The Oral NK 1 Antagonist Aprepitant for Prevention of Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy

By Ronald de Wit  

American Journal of Cancer, Vol. 4, Iss. 1, 2005-01 ,pp. : 35-48

Adis International

Access to resources Recommend Favorite

Effectiveness of palonosetron for preventing delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy in patients with gastrointestinal cancer

By Murakami Michiyasu   Hashimoto Hiroki   Yamaguchi Kyohei   Yamaguchi Ikuko   Senba Shozo   Siraishi Takeshi  

Supportive Care in Cancer, Vol. 22, Iss. 4, 2014-04 ,pp. : 905-909

Springer Publishing Company

Access to resources Recommend Favorite

The effect of palonosetron hydrochloride in the prevention of chemotherapy-induced moderate and severe nausea and vomiting

By                    

Experimental and Therapeutic Medicine, Vol. 5, Iss. 5, 2013-01 ,pp. : 1418-1426

Spandidos Publications

Access to resources Recommend Favorite

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer

By Navari Rudolph M  

Future Oncology, Vol. 6, Iss. 7, 2010-07 ,pp. : 1073-1084

Future Medicine

Access to resources Recommend Favorite

Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin

By Choi Chel   Kim Min   Park Jin-Young   Yoon Aera   Kim Ha-Jeong   Lee Yoo-Young   Kim Tae-Joong   Lee Jeong-Won   Kim Byoung-Gie   Bae Duk-Soo  

Supportive Care in Cancer, Vol. 22, Iss. 5, 2014-05 ,pp. : 1181-1187

Springer Publishing Company

Access to resources Recommend Favorite